X4 PHARMACEUTICALS, INC Operating Lease Cost
X4 PHARMACEUTICALS, INC (XFOR) reported Operating Lease Cost of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC operating lease, cost for the quarter ending 2026-06-30 was $400.00K, a 63.13% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, cost for the quarter ending 2026-03-31 was $400.00K, a 17.86% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, cost for the quarter ending 2025-12-31 was $406.00K, a 15.42% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, cost for the quarter ending 2025-09-30 was $142.00K, a 71.31% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, cost for fiscal 2025 was $2.12M, a 8.55% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC operating lease, cost for fiscal 2024 was $1.95M, a 6.29% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC operating lease, cost for fiscal 2023 was $2.08M, a 0.19% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC operating lease, cost for fiscal 2022 was $2.08M, a 0.34% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | $1.21M derived: sum of 3 quarters · filed 2026-08-06 | $1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-06 | $806.00K derived: sum of 2 quarters · filed 2026-05-06 | $948.00K derived: sum of 3 quarters · filed 2026-05-06 | $2.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $406.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $548.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.63M derived: sum of 3 quarters · filed 2026-08-06 | $2.12M 10-K · filed 2026-03-17 |
| 2025-09-30 | $142.00K 10-Q · filed 2025-11-05 | $1.23M derived: sum of 2 quarters · filed 2026-08-06 | $1.71M 10-Q · filed 2025-11-05 | $2.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.08M 10-Q · filed 2026-08-06 | $1.57M 10-Q · filed 2026-08-06 | $2.05M derived: sum of 3 quarters · filed 2026-08-06 | $2.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $487.00K 10-Q · filed 2026-05-06 | $967.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.46M derived: sum of 3 quarters · filed 2026-05-06 | $1.95M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $975.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.46M derived: sum of 3 quarters · filed 2026-03-17 | $1.95M 10-K · filed 2026-03-17 |
| 2024-09-30 | $495.00K 10-Q · filed 2025-11-05 | $984.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.47M 10-Q · filed 2025-11-05 | $2.00M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $489.00K 10-Q · filed 2025-08-08 | $978.00K 10-Q · filed 2025-08-08 | $1.50M derived: sum of 3 quarters · filed 2026-03-17 | $2.02M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $489.00K 10-Q · filed 2025-05-01 | $1.01M derived: sum of 2 quarters · filed 2026-03-17 | $1.53M derived: sum of 3 quarters · filed 2026-03-17 | $2.05M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.04M derived: sum of 2 quarters · filed 2026-03-17 | $1.56M derived: sum of 3 quarters · filed 2026-03-17 | $2.08M 10-K · filed 2026-03-17 |
| 2023-09-30 | $518.00K 10-Q · filed 2024-11-13 | $1.04M derived: sum of 2 quarters · filed 2024-11-13 | $1.56M 10-Q · filed 2024-11-13 | $2.08M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $521.00K 10-Q · filed 2024-08-08 | $1.04M 10-Q · filed 2024-08-08 | $1.56M derived: sum of 3 quarters · filed 2025-03-26 | $2.07M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $522.00K 10-Q · filed 2024-05-07 | $1.04M derived: sum of 2 quarters · filed 2025-03-26 | $1.55M derived: sum of 3 quarters · filed 2025-03-26 | $2.07M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $519.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.03M derived: sum of 2 quarters · filed 2025-03-26 | $1.55M derived: sum of 3 quarters · filed 2025-03-26 | $2.08M 10-K · filed 2025-03-26 |
| 2022-09-30 | $507.00K 10-Q · filed 2023-11-09 | $1.03M derived: sum of 2 quarters · filed 2023-11-09 | $1.56M 10-Q · filed 2023-11-09 | $2.09M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-06-30 | $524.00K 10-Q · filed 2023-08-10 | $1.05M 10-Q · filed 2023-08-10 | $1.59M derived: sum of 3 quarters · filed 2024-03-21 | $2.12M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-03-31 | $530.00K 10-Q · filed 2023-05-04 | $1.06M derived: sum of 2 quarters · filed 2024-03-21 | $1.60M derived: sum of 3 quarters · filed 2024-03-21 | $2.14M derived: sum of 4 quarters · filed 2024-03-21 |
| 2021-12-31 | $533.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.07M derived: sum of 2 quarters · filed 2024-03-21 | $1.61M derived: sum of 3 quarters · filed 2024-03-21 | $2.09M 10-K · filed 2024-03-21 |
| 2021-09-30 | $537.00K 10-Q · filed 2022-11-03 | $1.08M derived: sum of 2 quarters · filed 2022-11-03 | $1.55M 10-Q · filed 2022-11-03 | $2.00M derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-06-30 | $541.00K 10-Q · filed 2022-08-04 | $1.02M 10-Q · filed 2022-08-04 | $1.46M derived: sum of 3 quarters · filed 2023-03-21 | $1.87M derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-03-31 | $476.00K 10-Q · filed 2022-05-12 | $919.00K derived: sum of 2 quarters · filed 2023-03-21 | $1.33M derived: sum of 3 quarters · filed 2023-03-21 | $1.55M derived: sum of 4 quarters · filed 2023-03-21 |
| 2020-12-31 | $443.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $856.00K derived: sum of 2 quarters · filed 2023-03-21 | $1.07M derived: sum of 3 quarters · filed 2023-03-21 | $1.29M 10-K · filed 2023-03-21 |
| 2020-09-30 | $413.00K 10-Q · filed 2021-11-04 | $629.00K derived: sum of 2 quarters · filed 2021-11-04 | $847.00K 10-Q · filed 2021-11-04 | $1.06M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $216.00K 10-Q · filed 2021-08-03 | $434.00K 10-Q · filed 2021-08-03 | $651.00K derived: sum of 3 quarters · filed 2022-03-17 | $876.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $218.00K 10-Q · filed 2021-05-06 | $435.00K derived: sum of 2 quarters · filed 2022-03-17 | $660.00K derived: sum of 3 quarters · filed 2022-03-17 | $858.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $217.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $442.00K derived: sum of 2 quarters · filed 2022-03-17 | $640.00K derived: sum of 3 quarters · filed 2022-03-17 | $827.00K 10-K · filed 2022-03-17 |
| 2019-09-30 | $225.00K 10-Q · filed 2020-11-05 | $423.00K derived: sum of 2 quarters · filed 2020-11-05 | $610.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $198.00K 10-Q · filed 2020-08-04 | $385.00K 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $187.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |